Evidence map›Paper›PMID 29404860›Full record

ArticleInternational ophthalmology2019

Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration.

Alexandros Rouvas, Irini Chatziralli, Angeliki Androu, Panagiota Mpougatsou, Dimitrios Alonistiotis, Maria Douvali, Stamatina A Kabanarou, Panagiotis Theodossiadis

Abstract read
PubMed Publisher
In one paragraph

Article in International ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alexandros Rouvas2nd Department of Ophthalmology, Attikon Hospital, University of Athens, 28, Papanastasiou Street, Agios Dimitrios, 17342, Athens, Greece.
Irini Chatziralli2nd Department of Ophthalmology, Attikon Hospital, University of Athens, 28, Papanastasiou Street, Agios Dimitrios, 17342, Athens, Greece. eirchat@yahoo.gr.
Angeliki Androu2nd Department of Ophthalmology, Attikon Hospital, University of Athens, 28, Papanastasiou Street, Agios Dimitrios, 17342, Athens, Greece.
Panagiota Mpougatsou2nd Department of Ophthalmology, Attikon Hospital, University of Athens, 28, Papanastasiou Street, Agios Dimitrios, 17342, Athens, Greece.
Dimitrios Alonistiotis2nd Department of Ophthalmology, Attikon Hospital, University of Athens, 28, Papanastasiou Street, Agios Dimitrios, 17342, Athens, Greece.
Maria Douvali2nd Department of Ophthalmology, Attikon Hospital, University of Athens, 28, Papanastasiou Street, Agios Dimitrios, 17342, Athens, Greece.
Stamatina A KabanarouMedical Retina Department, Korgialeneio Benakeio, Red Cross Hospital, Athens, Greece.
Panagiotis Theodossiadis2nd Department of Ophthalmology, Attikon Hospital, University of Athens, 28, Papanastasiou Street, Agios Dimitrios, 17342, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare the efficacy and safety of two intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents, ranibizumab and aflibercept, for the treatment of vascularized pigment epithelium detachment (vPED) due to age-related macular degeneration (AMD) in a follow-up time of 12 months.

methodsParticipants in this study were 71 patients (71 eyes) with vPED due to AMD, who were treated with intravitreal 0.5 mg ranibizumab (n = 38) or 2.0 mg aflibercept (n = 33) and had at least 12-month follow-up. All patients underwent best-corrected visual acuity (BCVA) measurement and optical coherence tomography at baseline and at every visit. The PED height, the presence of subretinal fluid (SRF), intraretinal fluid and diffuse macular edema (DME) were recorded at each visit.

resultsThere was a statistically significant difference in BCVA between the two groups at month 12 in favor of aflibercept. However, both agents were found to improve or stabilize BCVA in the majority of patients at the end of the follow-up. The change in PED height did not differ significantly between the two groups at the end of the follow-up with similar number of injections. At month 12, there was a significant improvement in SRF presence in both groups compared to baseline.

conclusionsAlthough aflibercept was found to be superior to ranibizumab regarding BCVA improvement, both agents showed anatomical effectiveness with significant reduction in PED height and SRF absorption in patients with vPED due to AMD.

Indexed as

AgedAngiogenesis InhibitorsDose-Response Relationship, DrugFemaleFluorescein AngiographyFundus OculiHumansIntravitreal InjectionsMaleRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal DetachmentRetinal Pigment EpitheliumRetrospective StudiesTomography, Optical CoherenceafliberceptAngiogenesis InhibitorsRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsAfliberceptAge-related macular degenerationPigment epithelium detachmentRanibizumabTreatment

Identifiers

PMID29404860

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.